Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 28 Carcinoma, Non-Small-Cell Lung 27 Colorectal Neoplasms 17 Esophageal Squamous Cell Carcinoma 14 Stomach Neoplasms 13 Squamous Cell Carcinoma of Head and Neck 13 Esophageal Neoplasms 12 Cholangiocarcinoma 10 Lung Neoplasms 9 Head and Neck Neoplasms 9 Uterine Cervical Neoplasms 8 Small Cell Lung Carcinoma 8 Triple Negative Breast Neoplasms 7 Rectal Neoplasms 7 Nasopharyngeal Carcinoma 6 Melanoma 5 Colonic Neoplasms 5 Recurrence 4 Pancreatic Neoplasms 4 Locally Advanced Rectal Cancer 4 Hodgkin Disease 4 Neoplasms 3 NSCLC 3 Lymphoma, Extranodal NK-T-Cell 3 Glioblastoma 3 Carcinoma, Transitional Cell 3 Biliary Tract Neoplasms 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Thyroid Neoplasms 2

Interventions

tislelizumab 1 regorafenib 1 Trace amine-associated receptor 1 1 Thymalfasin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × MCRC × tislelizumab × Clear all

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting

MCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡